Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief

This article was originally published in The Tan Sheet

Executive Summary

Valeant buys Brazilian nutrition firm Probiotica; Nutraceutical International keeps up acquisitions; Claritin weighs on Merck consumer in Q4; J&J acetaminophen study backs Glaxo; more news In Brief.

You may also be interested in...

Valeant Includes OTCs In Bid For Dramatic Growth By 2013

The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.

Glaxo Acetaminophen Efficacy Studies Fill FDA's 1,000-MG Dose Data Gaps

GlaxoSmithKline generated clinical data supporting the greater pain-relief efficacy of 1,000 mg of acetaminophen over 500-mg and 650-mg doses, urging FDA to maintain OTC status for the high dose.

Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo

Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts